Mirkin B L, Green T P, O'Dea R F
Eur J Clin Pharmacol. 1980 Jul;18(1):109-16. doi: 10.1007/BF00561487.
The pharmacodynamic actions and disposition of diuretic and antihypertensive agents may be significantly modified in subjects with renal disease. Most studies on this question have dealt with alterations in the elimination kinetics of these drugs and, while they generate descriptive data, minimal insight about changes in dose-response relationships or mechanisms of drug action are provided by such investigations. Several basic principles which may serve as useful guidelines in determining how renal failure will influence the response to drugs have been considered. They include the following: degree of renal malfunction, intrinsic toxicity of the drug, alternative pathways for drug metabolism and elimination, elimination pharmacokinetics and dose-response characteristics. Several classes of diuretic agents (thiazides, furosemide) and antihypertensive drugs (hydralazine, methylopda, propranolol, prazosin, and clonidine) have been used as models to define how basic knowledge of renal and non-renal pathways for elimination of drugs and their pharmacodynamic actions may assist in establishing rational therapeutic regimens for these agents in patients with renal failure.
肾病患者体内利尿剂和抗高血压药物的药效学作用及处置情况可能会发生显著改变。关于这个问题的大多数研究都集中在这些药物消除动力学的改变上,虽然这些研究能生成描述性数据,但对于剂量-反应关系的变化或药物作用机制,此类研究提供的见解极少。人们已经考虑了几个基本原则,这些原则可能有助于指导确定肾衰竭将如何影响药物反应。它们包括以下几点:肾功能不全的程度、药物的内在毒性、药物代谢和消除的替代途径、消除药代动力学以及剂量-反应特征。几类利尿剂(噻嗪类、呋塞米)和抗高血压药物(肼屈嗪、甲基多巴、普萘洛尔、哌唑嗪和可乐定)已被用作模型,以确定关于药物肾内和非肾内消除途径及其药效学作用的基础知识,如何有助于为肾衰竭患者制定这些药物的合理治疗方案。